You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Retargeting FDA Approved Anticancer Liposomal Drugs to Cancer Stem Cells

    SBC: ZoneOne Pharma            Topic: O

    DESCRIPTION provided by applicant The goal of this research is to develop a ligand product and facile method to use it to target FDA approved liposomal anticancer drugs to cancer stem cells that overexpress CD We have devised a highly efficient chemo enzymatic synthesis of a hyaluronan lipid HA lipid ligand and have teamed with ZoneOne Pharma to develop a simple and robust micelle transfer ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  2. Maximizing cancer synthetic lethality using dual PI-3K/PARP inhibitors

    SBC: SignalRx Pharmaceuticals Inc.            Topic: NCI

    PARP inhibitors PARPi are particularly efficacious in tumors deficient in the BRCA tumor suppressor genes but of limited activity in BRCA competent tumors There is an unmet medical need to develop targeted therapeutic agents which will augment PARPi activity for BRCA wild type cancers and to increase chemo radiosensitivity in these malignancies BRCA proteins are essential components ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  3. Simvastatin nanomedicine in ARDS and sepsis

    SBC: EUNOIA BIOTECH LLC            Topic: 400

    Title Simvastatin nanomedicine in ARDS and sepsis The host response to severe infection termed sepsis affects more than million Americans yr generating annual direct costs exceeding $ billion Novel therapies are sorely needed to target maladaptive features of the host response that complement antimicrobial drugs and advances in supportive care Microcirculatory hyperpermeability may be a ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  4. A universal vaccine for the prevention of meningococcal meningitis in Africa

    SBC: OMVAX INC            Topic: R

    For more than years sub Saharan Africa has suffered with high rates of endemic meningococcal disease and periodic epidemic epidemics involving over cases In a low cost serogroup A polysaccharide protein conjugate vaccine MenAfriVac was introduced in the region The vaccine confers protection against serogroup A MenA disease as well as asymptomatic nasopharyngeal MenA carria ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  5. Highly specific ATR inhibitors for the targeted treatment of a broad spectrum of cancers

    SBC: Atrin Pharmaceuticals            Topic: 103

    PROJECT SUMMARY Specific targeting of the Ataxia Telangiectasia and Rad related kinase ATR represents an emerging strategy to treat a broad spectrum of cancers most notably those that currently lack effective treatments Suppression of ATR selectively kills cells subjected to oncogenic stress alternative lengthening of telomeres ALT or loss of double strand break DSB repair mechanisms A ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  6. Vulnerable Plaque Amplified Optical Analyzer

    SBC: Energy Research Company            Topic: NHLBI

    DESCRIPTION provided by applicant Energy Research Company ERCo in a collaboration with The City College of New York CCNY and Columbia University Medical Center CUMC proposes developing the Vulnerable Plaque Amplified Optical Analyzer VPAOA a fiber optic catheter instrument based on patented amplified spectroscopy technology for detecting and analyzing vulnerable plaque VP in corona ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  7. A Low-Cost Portable Multiplex Serum Molecular Test for HBV and HCV Detection

    SBC: LENIMA FIELD DIAGNOSTICS LLC            Topic: R

    DESCRIPTION provided by applicant Hepatitis B HB and hepatitis C HC are two of the most widespread infections worldwide caused by the blood borne HB virus HBV and HC virus HCV respectively About million and million people suffer from chronic HB CHB and chronic HC CHC respectively while about and people die each year due to the consequence of HB and ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  8. DEVELOPMENT OF SMALL MOLECULE THERAPEUTICS AGAINST RNA VIRUSES

    SBC: FOX CHASE CHEMICAL DIVERSITY CENTER INC.            Topic: R

    DESCRIPTION provided by applicant The ultimate goal of this project is to produce a broad spectrum drug for the treatment of viral infections caused by filoviruses Ebola and Marburg arenaviruses Lassa fever and rhabdoviruses rabies We and others have determined that efficient budding of these emerging human pathogens is dependent on the subversion of host proteins such as Nedd and t ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  9. Temozolomide Perillyl Alcohol Conjugate as Treatment for Recurrent Malignant Brain tumors

    SBC: NEONC TECHNOLOGIES INC            Topic: BT

    DESCRIPTION provided by applicant Glioblastoma multiforme GBM the most common and malignant of all gliomas has a median survival time of months Standard of care chemotherapy using temozolomide TMZ is effective initially but the GBM inevitably recurs and these recurrent tumors are resistant to TMZ There are currently no effective treatment options for patients with TMZ resistant ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  10. Ultrasensitive Point-of-Care Diagnostics of Viral Biomarkers and Infectious Diseases

    SBC: ARISAN THERAPEUTICS INC            Topic: NIAID

    Project Summary Linking infectious agent diagnostics to clinical decision making at the point of care requires a fast highly sensitive and simple to use method that takes into account the infrastructure and workflow in clinical settings of both developing and developed regions In addition being able to distinguish among multiple potential infectious pathogens in a single test is of great impor ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government